Zoom webinar comments and infoAgreed that the webinar was a little slow and laid back on how it was run, however, there was some new information. One of the host says it is oneof his top 5 stocks he has invested in.....a believer !! ( so he may be slightly prejudiced in his comments ).
Ifenprodil shows it has good potential in several other health areas as well. If they had the finances they would like to be doing 5 different trials right now if the could. One of the hosts and Moreau said they just received some anayst report information this morning but hadn't had a chance to go thru it in detail yet, however, it was suggesting the stock should be .80. Moreau suggests with good phase 2 results that the stock should really start moving ( he said even before the actual results come out ). He feels that that is when institutions and big pharma really would take notice and be calling them instead of Algernon always trying to chase them to get noticed.They are working on the transfusion drip formulation and seem to be getting close to that. Indicated that when they do they would be trying to obtain emergency status to use with the FDA ( which the FDA could do on a temporary approval basis because it could help save lives ASAP ) at the same time when they would be starting phase 3. They have enough financing for now but will need more to do phase 3. Financing could come form them raising it or maybe joint venture/outside financing, etc.. His preference was not to dilute the stock.
Overall, company has amazingly GREAT potentional if phase 2 goes well !!